[Comparative analysis of the use of levamisole and pyrogenal in the treatment of multiple sclerosis].
A series of 120 patients with multiple sclerosis was subjected to a clinico-immunological examination and treatment. In a group of patients receiving levamisole, improvement of the neurologic symptomatology was observed in 65% of the cases and that of the immunological indices in 97.5%. Pyrogenal treatment led to no improvement in the immunological parameters. Clinical improvement in this group was seen in only 17.8% of the patients. It is recommended that treatment with levamisole be conducted following the preliminary assessment of the sensitivity of the patient's lymphocytes to the drug in vitro.
D000293:Adolescent; D000328:Adult; D001402:B-Lymphocytes; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007958:Leukocyte Count; D007978:Levamisole / Q000494:pharmacology / Q000627:therapeutic use*; D008070:Lipopolysaccharides / Q000627:therapeutic use*; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology; D013601:T-Lymphocytes
D008070:Lipopolysaccharides; C009136:pyrogenal; D007978:Levamisole
Sravnitel'nyĭ analiz primeneniia levamizola i pirogenala pri lechenii rasseiannogo skleroza.